In short
Clinical trials are investigating Vilobelimab in people with ulcerative pyoderma gangrenosum, a painful skin condition that can cause deep ulcers. These studies look at whether Vilobelimab is safe and effective, especially compared with placebo, and measure how well ulcers heal.
Key points
- Vilobelimab is being studied in clinical trials for ulcerative pyoderma gangrenosum, a rare skin condition that causes painful ulcers. The main trial in the source data is a Phase 3 study and is completed. It was randomized, double-blind, placebo-controlled, and multicenter, which means patients were assigned by chance, neither side knew the treatment, and the study was done at several centers. The trial compared Vilobelimab with placebo to see if more patients could achieve complete closure of the target ulcer. The study enrolled 149 patients and focused on healing as the main outcome.
Trial overview
The source data includes one clinical trial of Vilobelimab in people with ulcerative pyoderma gangrenosum, a rare skin disease that can cause deep and painful ulcers. The study was designed to test whether Vilobelimab could improve healing compared with placebo.
Study design and phase
This was a Phase 3 trial, which is a late-stage study used to check how well a treatment works and how safe it is in a larger group of patients. It was also randomized, double-blind, placebo-controlled, multicenter, and adaptive.
Randomized means patients were placed into groups by chance. Double-blind means neither the patients nor the study team knew who got Vilobelimab or placebo during the trial. Placebo-controlled means the study compared Vilobelimab with an inactive treatment, so the results could be judged more fairly.
Who participated
The trial enrolled 149 patients with ulcerative pyoderma gangrenosum. The source data does not list more detailed entry rules, such as age limits or other health requirements.
What was measured
The main endpoint, or main result the study wanted to measure, was the proportion of patients achieving complete closure of the target ulcer by the end of treatment. Complete closure meant the ulcer was fully covered by new skin or scar tissue, with no drainage and no need for dressings, and this had to be confirmed at two study visits 2 weeks apart.
This outcome focuses on real healing of the wound, not just smaller size or less pain.
Trial interventions and comparison
The study compared Vilobelimab given by intravenous use with placebo given by intravenous use. The trial record also lists several corticosteroid medicines, such as prednisolone, prednisone, dexamethasone, hydrocortisone, methylprednisolone, betamethasone, triamcinolone, cortisone acetate, and fludrocortisone, as part of the intervention record.
In simple terms, the study was set up to see whether adding Vilobelimab led to better ulcer healing than the comparison treatment.
What the study tracked over time
The trial measured healing up to and including the end of treatment visit. The healing check had to be repeated at two visits 2 weeks apart to confirm that the ulcer was truly closed and not just temporarily improved.
The study status is listed as Completed, which means the planned trial activities were finished.